Cytokine Signalling Forum

Publications




Professor Iain McInnes Reviews the Most Important Papers from 2017

McInnes I. - Please click the links below to go to the CSF review of each paper.

2017 was a successful year for rheumatoid arthritis research, with some key advances in JAK inhibitors and IL-6 inhibitors, as outlined below.

- Tofacitinib was suggested as a potential treatment for psoriatic arthritis, and NICE recommended tofacitinib as
a treatment for moderate to severe rheumatoid arthritis
- Baricitinib studies supported the potential use of baricitinib as a treatment for rheumatoid arthritis
- Filgotinib Phase 2 studies suggested that filgotinib could be effective as monotherapy or combination therapy
for the treatment of rheumatoid arthritis
- Upadacitinib was efficacious in Phase 2 studies and entered Phase 3
- Subcutaneous tocilizumab proved efficacious and had a comparable safety profile to intravenous tocilizumab

Tofacitinib:
Efficacy and Safety of Tofacitinib Monotherapy, Tofacitinib with Methotrexate, and Adalimumab with Methotrexate in Patients with Rheumatoid Arthritis (ORAL Strategy): A Phase 3b/4, Double-Blind, Head-To-Head, Randomised Controlled Trial.
The Lancet - Fleischmann R, Mysler E, et al.

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
The New England Journal of Medicine - Gladman D, Rigby W, et al.

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
The New England Journal of Medicine - Mease P, Hall S, et al.

Baricitinib:
Baricitinib in Patients with Inadequate Response or Intolerance to Conventional Synthetic DMARDs: Results from the RA-BUILD Study.
Annals of Rheumatic Diseases - Dougados M, van der Heijde D, et al.

Safety and Efficacy of Baricitinib through 128 Weeks in an Open-label, Long-term Extension Study in Patients with Rheumatoid Arthritis.
The Journal of Rheumatology - Keystone EC, Genovese MC, et al.

Filgotinib:
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Annuls of Rheumatic Diseases - Westhovens R, Taylor PC, et al.

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Annuls of Rheumatic Diseases - Kavanaugh A, Kremer J, et al.

Upadacitinib:
A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy.
Arthritis & Rheumatology - Kremer JM, Emery P, et al.

Tocilizumab:
Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-naïve Patients with Early Rheumatoid Arthritis: 2-year Clinical and Radiographic Results from the Randomized, Placebo-controlled FUNCTION Trial.
Annuls of Rheumatic Diseases - Burmester GR, Rigby WF, et al.

Review:
Pathogenetic Insights from the Treatment of Rheumatoid Arthritis.
The Lancet - McInnes I, Schett G.

Access original article via Pubmed

Upload date: February 2018

Article image